

Index

A

- Abacavir hypersensitivity, 481–482
- Acetaminophen (APAP), 5, 7–9, 12, 14, 15, 168–175, 184, 185, 370, 385, 393
 - ALT elevation, 174
 - covalent binding, 275–277, 279, 282, 286, 289, 291, 296, 297
 - GSH depletion, 274–279, 282, 283, 285, 286, 289, 291, 296, 301
 - metabolic activation, 184, 185
 - N*-acetylcysteine, 174
 - N*-acetyl-*p*-benzoquinoneimine (NAPQI), 174, 277–280, 283, 285, 289, 291, 295, 296, 300, 301
 - necrotic *vs.* apoptotic death, 272–273
 - role of JNK signaling, 284, 289, 290, 296
 - ROS generation, 274, 279, 295
 - signaling pathways activated, 285, 291
- Acetaminophen-induced liver injury (AILI), 209, 216–217
- Acetaminophen-protein adducts, 373
- N*-Acetyl-*m*-aminophenol (AMAP), 277, 279, 295
- Action potential, 80–82, 84, 86, 88, 95–98
- Action potential duration (APD), 80, 88, 89, 95–97
- Acute allergic interstitial nephritis (AIN), 120–121
- Acute generalized exanthematous pustulosis (AGEP)
 - cutaneous/systemic reactions, 45, 46
 - keratinocytes, 47
 - pustular drug eruption, 46
- Acute liver failure, 370, 375
- Acute phosphate nephropathy, 123
- Acute tubular necrosis (ATN)
 - aminoglycosides, 117–118
 - amphotericin B, 119–120
 - platin-containing compounds, 118–119
 - radiocontrast media, 118
- Acyl glucuronide reaction, 521
- Adduct, 10, 11, 13, 16, 17
- Adjuvant, 496
- Adverse drug reactions (ADRs), 166, 182, 185, 234, 252, 421
 - classification, 167
 - danger model implications, 498
- Agranulocytosis, 498, 502
- Alanine aminotransferase (ALT), 371–373, 376, 378, 381, 385, 386, 389, 392, 420–421
- Allergic hepatitis, 208
- Amadori-like process, 533
- Aminobenzotriazole, 446, 447
- Amodiaquine, 178, 184–185
 - bioactivation, 184
 - modification, 185
- Amphotericin B, 119–120
- Analgesics, 124
- Angiogenesis, 462–463
- Angiotensin II receptor blockers (ARBs), 115
- Animal models, 502, 504–506
- Anionic uncouplers
 - mitochondrial membrane potential, 328

- mitochondrial permeability transition (MPT), 329
 - mitochondrial respiration, 328
 - respiratory chain, 327
 - Antagonist, 80, 82, 85–87, 96, 97
 - Anthracyclines, 99–101
 - Antiarrhythmic, 81, 91–94, 97
 - Antibodies
 - abciximab-induced, 64
 - drug-dependent, 59–64, 66, 67, 69, 71
 - hapten-specific, 59, 61–63
 - penicillin-induced, 59, 62
 - RGD mimetic-induced, 64
 - Antibody-mediated, 505
 - Antibody-mediated drug hypersensitivity, 34–35
 - Anticonvulsants, 503, 504
 - Antiepileptic drug (AED), 133, 151
 - Antigenicity, adaptive immune system, 34
 - Anti-inflammatory cytokines, 384, 386
 - Antioxidant response element (ARE), 234–242, 244, 249, 251
 - Aplastic anemia, 72
 - clinical presentation, 73
 - diagnosis, 73
 - drugs implicated in, 73
 - pathogenesis, 72–73
 - treatment, 74
 - Apoptosis, 371, 372, 383, 384, 390
 - Apoptosis signaling-regulating kinase 1 (ASK-1), 279–282, 293
 - Aristolochic acid, 123
 - Arrhythmia, 79–82, 87, 95–97
 - Aryl hydrocarbon receptor (AHR), 132, 135, 139–148
 - ligands, 140, 143, 144
 - metabolism, 143–144
 - perturbation, 143
 - phenotypes, 142
 - phylogenetic evidence, 139–140
 - signaling pathway, 140–141
 - TCDD, 140, 145
 - teratogenesis, 145–147
 - toxicity, 141–142
 - Aryl hydrocarbon receptor nuclear translocator (ARNT), 140–142, 146
 - Aryl hydrocarbon responsive element (AHRE), 132, 140–142
 - Asparatate aminotransferase (AST), 371, 373, 376, 385
 - Ataxia telangiectasia mutated (ATM), 156
 - ATP, 374, 381–384, 389, 394
 - Autoantibodies, 426, 427
 - alpha methyl dopa-induced, 60
 - drug-induced, 60, 62
 - Autoimmunity, 495, 497, 505
- B**
- Basic leucine zipper (bZip), 235, 236, 238
 - Bax, 384, 390, 393
 - Bcl-2, 384, 393
 - Benzo[a]pyrene (B[a]P), 138–139, 143, 149–151
 - Bevacizumab
 - angiogenesis, 462–463
 - arterial thrombosis, 463–464
 - platelet activation, 464–465
 - Bioactivation, 32–33, 132, 135, 138, 143, 149–152
 - Biologics
 - adverse events, 455–457
 - bevacizumab, 462–465
 - interleukin-12 (IL-12), 461–462
 - non-pharmacologically mediated toxicities, 467–470
 - pharmacologically mediated toxicities, 459–467
 - superagonist anti-CD28 monoclonal antibody, 465–467
 - toxicity mechanisms, 458–459
 - trastuzumab, 459–460
 - types, 455–457
 - vaccines, 471–472
 - Biomarkers, troglitazone-induced hepatotoxicity, 424–425
 - Biopharmaceutical products, 486
 - Blood flow, 375–377
 - Bromobenzene, 172, 174–176
- C**
- Ca channels, 80, 84–87, 89, 97
 - Cap ‘n’ collar (CNC), 235, 236, 238

- Carbamazepine (CBZ) hypersensitivity, 482–483
- Carbon tetrachloride (CCl₄), 175–177, 291
- Cardioglycosides, 80, 82, 83, 89
- Catalase, 155
- Cell-mediated, 495
- Cellular dysfunction, 117
- Centrilobular hepatic necrosis, 370, 376
- Channel blocker, 80, 81, 85, 86, 92, 97
- Chemical/oxidative stress, 236, 239, 241, 242, 244, 246, 247, 251
- Chemokines, 384–388, 391
- Chinese herb nephropathy, 123
- Chloroquine, 184, 185
- Chronic interstitial nephritis
 - aristolochic acid, 123
 - cyclosporine, 122
 - lithium, 121–122
- Cockayne syndrome B (CSB), 156
- Coenzyme A (CoA), 520
- Conduction block, 86
- Contact hypersensitivity syndrome (CHS) model, 202
- Costimulatory, 495
- Covalent binding, 372–375, 383, 392, 393, 499, 503, 504
 - animal vs. human, 522
 - chemical structure, 526
 - drug-related material, 527
 - gold standard approach, 522
 - limitations, 524–525
 - metabolic pathway, 526, 527
 - oxazolidinedione (OZD) derivative, 523
 - peroxisome proliferator activated receptor- γ (PPAR γ), 523
 - quantitative information, metabolic activation, 524
 - thiazolidinedione (TZD) ring-system, 523
- CuI₃, 240, 241, 244, 247–249
- Cutaneous reactions
 - acute generalized exanthematous pustulosis (AGEP), 45–47
 - CD8+ vs. CD4+ T cells, cytotoxicity, 44
 - drug rash with eosinophilia and systemic symptoms (DRESS), 49–50
 - flare up reactions, 51–52
 - maculopapular exanthem (MPE), 44–45
 - multiple drug hypersensitivity, 50–51
 - rashes, 43
- Cu,Zn-SOD, 286
- Cyclin-dependent kinases (CDKs), 429
- Cyclooxygenase-2 (COX-2) inhibitors, 115–116, 385, 388
- Cyclosporine, 122
- Cyclosporine A, 382, 383, 389
- CYP3A activity, 535, 536
- CYP2E1, 277, 280, 283, 284, 286, 295, 301, 372, 379, 380, 386, 393
- CYP isoforms, 372
- Cytochrome P450, 132, 137, 141, 143–145, 148–151, 377, 393
 - CY3A, 148
 - CYP1, 141, 144–145
 - CYP1A1, 141, 143–145, 149
 - Cyp1a1*, 145
 - CYP1A2, 144–145, 149
 - Cyp1a2*, 145
 - CYP1B1, 144
 - CYP2B, 148
 - CYP2C19, 149, 422
 - CYP2C8, 422
 - CYP2S1, 144
 - CYP3A4, 422–424, 430
 - CYP3A5, 149
 - CYP3A7, 150
- Cytokines, 384–388, 391, 392, 394, 444
 - animal models, DILI, 208–209
 - definition, 196–197
 - delayed skin, 200–203
 - drug-induced autoimmunity (DIAI), 203–206
 - drugs potential, 220
 - hepatoprotective cytokines, 212–216
 - hepatoprotoxicant cytokines, 209–212
 - human studies, DILI, 216–218
 - immediate skin, 197, 199
 - infusion-related toxicities, 207
 - interventional therapies development, 220
 - major functions, 197, 198
 - susceptibility, concomitant viral infections, 218–219
 - susceptible individuals prediction, 220
 - Th17 cells and IL-17, 219–220
- Cytosolic cytochrome, 318

Cytotoxicity, troglitazone-induced
hepatotoxicity, 423–424

D

Damage, 494–497, 499–502

Danger hypothesis, 493–506

D-drugs, 334

Deaths, 370, 384

Delayed after depolarization (DAD), 80–82,
89

Delayed skin

contact hypersensitivity syndrome
(CHS), 202

cytokines role, 201–202

drug hypersensitivity syndrome (DHS),
201

fixed drug eruptions (FDE)/exanthema
pustulosus, 200

human studies, 203

maculopapular exanthema, 200

nevirapine-induced skin rash, Brown
Norway (BN) rats, 202–203

SJS/TEN, 201

Deoxyribonuclease 1 (DNASE1), 287

Depolarization, 78, 80, 81, 84, 88, 93, 94

Detoxification, 132, 138, 143, 149–150, 152

Deuterium (isotope effect), 447

Dideoxynucleosides and abacavir

chain termination, 333–334

mtDNA mutations, 335

ROS formation, 334–335

stimulation, mitochondrial biogenesis,
335

thymidine triphosphate (TTP) depletion,
334

zidovudine (AZT), 333

Dioxin. *See* 2,3,7,8-Tetrachlorodibenzo-
p-dioxin (TCDD)

Dispersion, 89, 95, 97, 98, 100

DMSO, 385, 393

DNA

damage, 134–136, 138, 149–150,
152–154, 156

fragmentation, 389, 390

polymerase, 334

repair, 154

DNA/mRNA, 78, 101

DNA polymerase, 334

D-penicillamine (D-Pen)-induced
autoimmunity, 205–206

Drug hypersensitivity reactions, skin

acute generalized exanthematous

pustulosis (AGEP), 45–47

antibody-mediated drug hypersensitivity,
34–35

drug (-induced) hypersensitivity
syndrome (DHS/DiHS), 49–50

flare up reactions, 51–52

humans, 31

maculopapular exanthema (MPE), 44–45

multiple drug hypersensitivity syndrome,
50–51

naïve T cells stimulation, 32–34

T cell-mediated drug hypersensitivity,
35–41

TEN and SJS, 47–49

Drug hypersensitivity syndrome (DHS), 201

Drug-induced autoimmunity (DIAI)

central tolerance, reactive metabolite, 206

D-penicillamine (D-Pen)-induced
autoimmunity, 205–206

procainamide-and hydralazine-induced
autoimmunity, mice, 205

recombinant IFN- α , 204

TNF- α blockers, 204

Drug-induced liver injury (DILI)

acetaminophen, 332

acetaminophen-induced liver injury, 209,
216–217

alcohol, 331–332

allergic hepatitis, 208

animal models

LPS co-treatment, 292

Mn-SOD heterozygous mice, 292

anionic uncouplers, 327–329

aspirin, 343–344

ATP synthase inhibition, 340

clinical consequences, 318–322

decreased protein synthesis, 339–340

dideoxynucleosides and abacavir,
332–335

direct toxicity, reactive metabolites, 323

drug metabolism and excretion, 346–347

drugs, 217–218

endoplasmic reticulum stress, 330–331

- ex vivo cytokine production, 218
- fuel oxidation and energy production, 313–315
- halothane-induced liver injury, 208–209
- hepatoprotective cytokines, 212–216
- hepatoprototoxicant cytokines, 209–212
- idiosyncratic, 270–272, 292–294, 300–302
- immune reactions, 323–327
- inborn β -oxidation defects, 347–348
- inborn mitochondrial cytopathies, 347
- lipopolysaccharide (LPS), 209
- lysosomal permeabilization, 330
- membrane alterations and cell death, 316–318
- multiple initial targets, 331
- multiple mechanisms, 345–346
- nuclear DNA damage, 330
- obesity and nonalcoholic steatohepatitis, 350
- β -oxidation and respiration, primary impairment, 340–343
- peripheral benzodiazepine receptor (PBR) ligands, 330
- pregnancy, 349–350
- reactive oxygen species, aging, and cancer, 315–316
- role of mitochondria, 271, 274, 275, 277–284, 287–291, 293–301
- synthesis and stability, 338, 339
- tetracyclines, 344
- topoisomerases and binding, 336–338
- troglitazone, 330
- valproic acid, 343, 344
- viral infections, 348–349
- Drug-induced mitochondrial dysfunction
 - acetaminophen, 332
 - alcohol, 331–332
 - amineptine and tianeptine, 345
 - amiodarone, 341
 - anionic uncouplers, 327–329
 - antimalarial drugs, 342
 - aspirin, 343–344
 - ATP synthase, 340
 - benzaronone and benzobromarone, 342–343
 - buprenorphine, 342
 - calcium hopantenate, 345
 - cell-mediated immune responses, 325, 326
 - chloramphenicol and thiamphenicol, 339–340
 - ciprofloxacin and nalidixic acid, 337
 - cytotoxic T lymphocytes, 326, 327
 - dideoxynucleosides and abacavir, 332–335
 - diethylaminoethoxyhexestrol (DEAEH), 341
 - direct toxicity, reactive metabolites, 3223
 - endoplasmic reticulum stress, 330–331
 - erythromycins, 340
 - ethidium bromide, 338
 - fialuridine, 335
 - glucocorticoids, 345
 - humoral immune responses, 323–325
 - interferon- α , 338, 339
 - linezolid, 339
 - lysosomal permeabilization, 330
 - lysosomes, 340–341
 - 1-methyl-4-phenylpyridinium, 338
 - mild toxicity, 323
 - multiple mechanisms, 345–346
 - nonsteroidal antiinflammatory drugs, 345
 - nuclear DNA damage, 330
 - panadiplon, 345
 - pentamidine, 337
 - perhexiline, 341
 - peripheral benzodiazepine receptor (PBR) ligands, 330
 - pivampicillin, 345
 - polyamine analogs, 338
 - sensitive techniques, 324–325
 - tacrine and tamoxifen, 336, 337
 - tetracyclines, 344
 - topoisomerases, 336
 - troglitazone, 330
 - valproic acid, 343, 344
- Drug-induced nephrotoxicity mechanism
 - acute kidney injury (AKI), 112
 - glomerular disease, 124–125
 - hemodynamically-mediated kidney injury, 114–116
 - obstructive nephropathy, 126–128
 - renal vasculitis and thrombosis, 125–126
 - tubular epithelial cell damage, 117–120
 - tubulointerstitial disease, 120–124
 - types, 112–114
- Drug-induced QT interval prolongation, 485–486

Drug rash with eosinophilia and systemic symptoms (DRESS), 49–50

E

Early after depolarization, 80–82, 89, 96, 97
 Electrophilic reactive intermediates, 149–150
 ELISA, 373
 Embryonic and fetal development
 antiepileptic drug (AED), 133
 drug exposure, pregnancy, 133, 134
 human development and critical periods, 133, 136
 human teratogens, 133, 135
 windows of susceptibility, 133–134
 Endonuclease G, 384, 390
 Endothelial cells, 376, 377, 391, 392
 Ether-à-go-go-related gene, 89, 90
 Extracellular signal-regulated kinase (Erk), troglitazone, 428
 Ex vivo cytokine production, 218

F

Fas ligand (FasL), 48
 Fatty acid oxidation, 320, 321
 Fixed drug eruptions (FDE)/exanthema pustulosus, 200
 Flare up reactions, 51–52
 Flucloxacillin-induced cholestatic hepatitis, 484
 Focal segmental glomerulosclerosis (FSGS), 125
 Free radical reactive intermediates
 antioxidants and antioxidative enzymes, 154–155
 bioactivation, 151
 cellular macromolecules, oxidative damage, 153–154
 oxidative DNA damage, 156
 oxidative stress and reactive oxygen species (ROS), 152
 reactive nitrogen species (RNS), 153
 ROS/RNS-mediated signal transduction, 156
 Furosemide, 171, 175, 177

G

Gene transcription, 135, 139, 141, 144, 154
 Genetic predisposing factors, 485
 Glomerular disease, 124–125
 Glucose-6-phosphate dehydrogenase (G6PD), 154, 155
 Glutamylcysteine ligase (GCL), 276, 277, 285, 286, 289
 Glutathione (GSH), 149–150, 152, 156, 269, 270, 274–280, 282, 283, 285, 286, 289, 291, 295–297, 300, 301, 372–378, 380, 382, 383, 388, 391–394, 424, 425
 Glutathione depletion, 372, 375, 382, 383, 388, 393
 Glutathione S-transferase (GST), 138, 144, 149, 424–425
 Gold standard approach, 522
 GSH transferase, 374, 375
GSTM1, 425
GSTT1, 425

H

Halothane, 5, 8, 12–18
 Halothane-induced liver injury, 208–209
 Hapten, 499, 503, 505
 Heat shock proteins (HSP), 286, 296, 500, 501
 Hemodynamically-mediated kidney injury
 angiotensin-converting enzyme inhibitors (ACEI), 114–115
 calcineurin inhibitors, 116
 glomerular filtration rate (GFR), 114
 nonsteroidal anti-inflammatory drugs (NSAID), 115–116
 Hemolytic anemia
 clinical findings, 68, 71
 diagnosis, 61
 drug-induced, 59–61, 65, 70, 71
 drugs implicated in, 60
 treatment, 62
 Hepatic congestion, 371
 Hepatocyte suspensions, 375
 Hepatoprotective cytokines
 IL-4, 215
 IL-6, 213–214
 IL-10, 212–213
 IL-13, 213

- IL-4 and IL-10 synergism, 216
 - MCP-1, 214–215
 - MIP-2, 214
 - Hepatoprotocinant cytokines
 - IFN- γ , 210
 - IL-1, 211
 - MIF, 210
 - TNF- α , 211–212
 - Hepatotoxicity, 165–186, 440, 502, 503
 - dose of drug, 171
 - metabolic activation, 169
 - Higher-throughput surrogate assays,
 - bioactivation acceptable correlation, 530
 - assay format, 529
 - covalent binding, radioactivity, 529, 530
 - GSH, 528, 529
 - Merck drug discovery program, 529
 - radiolabeled synthesize, 528, 530
 - High mobility group box 1 (HMGB1), 500, 501
 - Hinge and latch model
 - DLG motif, 247, 248
 - ETGE motif, 247–249
 - H₂O₂, 269, 273–275, 277, 279, 280, 284, 285, 290
 - HPLC-EC, 374
 - Human immunodeficiency virus (HIV), 438, 439
 - Hydroxyl radicals (HO[•]) reaction, 154
 - Hypersensitivity reaction, troglitazone, 426–427
 - Hypersensitivity syndrome, 480, 503
 - Hypochlorite, 381
 - Hypomagnesemia, 119
- I**
- IC₅₀, 91, 93–95, 97
 - Idiosyncratic adverse drug reactions, 421, 430, 441, 446, 448, 496, 498–506
 - abacavir hypersensitivity, 481–482
 - biopharmaceutical products, 486
 - carbamazepine (CBZ) hypersensitivity, 482–483
 - consortia, 487
 - drug-induced QT interval prolongation, 485–486
 - familial occurrence, 479–480
 - flucloxacillin-induced cholestatic hepatitis, 484
 - hepatotoxicity, 419, 421, 430
 - metabolic idiosyncrasy, 479
 - multigenic and multifactorial nature, 480, 481
 - pharmacodynamic pathways, 480
 - statin-induced muscle toxicity, 484–485
 - toxicity, 419, 421
 - troglitazone, 421
 - Idiosyncratic hepatotoxicity, 178–185
 - IFN- γ , 210
 - IL-10, 385, 386
 - IL-11, 386
 - IL-13, 386
 - IL-10 promoter region, 199
 - Immediate skin reactions, 197, 199
 - Immune-mediated, 443, 496, 500, 503, 505
 - Immune modulator-induced DIAI, 204
 - Immunogenicity, innate immune system, 33–34
 - Immunohistochemical, 373, 374, 378, 379
 - Impaired mitochondrial function
 - outer membrane permeabilization/rupture, 318–319
 - primary impairment, β -oxidation, 320–321
 - primary impairment, respiration, 321–322
 - steatosis and cell dysfunction, 322
 - Inborn β -oxidation defects, 347–348
 - Inborn mitochondrial cytopathies, 347
 - Indoleamine-2,3-dioxygenase (IDO), 497
 - Inducible nitric oxide synthase (iNOS), 378, 379, 383, 385, 386, 392
 - Inflammation, 384–388
 - Instability, 95, 96
 - Interferon gamma (IFN γ), 385, 386, 388
 - Interleukin-6 (IL-6), 385, 386, 391, 392, 394
 - Interleukin-12 (IL-12)
 - administration, 461–462
 - biological activity, 461
 - toxicity mechanism, 462
 - Interleukin one beta (IL-1 β), 385, 387
 - Ion channel, 78, 84
 - Ionic current, 84
 - Ionic pump, 78, 82–83
 - Isoniazid, 178, 182–184
 - bioactivation, 183
 - Isoquine, 184, 185

J

- c-Jun N-terminal kinases (JNK), 388, 389
 - activation by ASK-1, 282
 - JNK1 vs. JNK2, 283–284
 - kinase-mediated cell toxicity pathway, 428–429
 - translocation to mitochondria, 279, 281–283, 289

K

- K channels, 80, 81, 84, 89–92
- Keap1
 - Cys-151, 241, 244, 251
 - Cys-273, 244, 251
 - Cys-288, 251
 - Keap1^{-/-} animals, 249, 251
 - modification, 252
- Keratinocytes, 45, 47
- α -Keto lactam derivative, 532
- Kinase-mediated cell toxicity pathway, 428–429
- Knockout mice
 - AHR, 142
 - DNA repair, 154, 156
- Kupffer cells, 380, 384–386

L

- β -Lactams, 121
- Lead optimization process, 522
- Lipid peroxidation, 377
- Lipopolysaccharide (LPS), 209, 291–294, 296
- Lipoxygenase (LPO), 151–152
- Liquid chromatography–mass spectrometry (LC–MS)-based approaches
 - acyl glucuronide reaction, 521
 - arene oxide trapping, glutathione, 516
 - coenzyme A (CoA), 520
 - cyanide trapping, 519, 520
 - DNA, 521
 - GSH adducts, 517, 518
 - mass defect filter-based approaches, 518
 - molecular ion(s) identification, 518
 - molecular mass determination, 516
 - quaternary ammonium derivative, 519
- Liver toxicity, 438, 439, 441

M

- Macrophage inhibitor protein 2 (MIP-2), 387, 388, 391
- Maculopapular exanthema (MPE), 44–45, 200
- Maf, 235
- Mannitol, 120
- Mass defect filter-based approaches, 518
- Maternal xenobiotic metabolism, 138
- M cells, 87–89
- Megakaryocyte derived growth factor (MDGF), 469
- Merck drug discovery program, 529
- Metabolic idiosyncrasy, 479
- Metabolism, 372–375, 380, 382, 383, 389, 392–394
- Metabolite, 9–11, 13, 15–18
- Metabolomics, 380
- Mice, 371–381, 383–392
- Microvascular injury, 376
- Minimizing metabolic activation, drug discovery
 - benign vs. toxic reactive intermediates, 537
 - bioactivation, 514
 - biology-based omic approaches, 537
 - chemical structural alerts, 514–515
 - covalent binding, 521–528
 - genotoxicity, 534–535
 - higher-throughput surrogate assays, 528–530
 - human-like *in vivo* conditions, 538
 - liquid chromatography–mass spectrometry (LC–MS)-based approaches, 517–521
 - P450 inactivation mechanism, 535–536
 - risk assessment, species-specific toxicity, 534
 - roadmap, 530–533
- Mitochondria, 99–101, 377, 379, 381–384, 389, 390, 393, 394
 - bax translocation, 281, 299
 - bcl-2 family members, 278, 279, 281, 290, 297, 301
 - dysfunction, drugs, 299
 - JNK translocation, 281–283, 299

- mitochondria permeability transition (MPT), 277, 278, 280–283, 289, 290, 297–300
 - Mitochondrial membrane potential, 383, 390, 394
 - Mitochondrial permeability transition (MPT), 318, 319, 381–383, 389, 393, 394
 - Mitochondrial respiration, 321, 322
 - Mitochondria-mediated toxicity, 428
 - Mn-SOD, 292–295, 297
 - Model hepatotoxins, 171–177
 - Monophasic action potentials (MAP), 95, 97
 - Multidrug resistant associated protein-2 (Mrp2), 426
 - Muscle damage mechanism, 485
 - Myocardium, 78, 79, 82–84, 89, 101
- N**
- N*-acetylcysteine, 372, 373, 375, 376, 380, 383, 386–388
 - N*-acetyl-*p*-aminophenol, 370
 - N*-acetyl-*p*-benzoquinone imine (NAPQI), 372, 373, 375, 377, 378, 380–383, 393, 394
 - Na channels, 80, 85
 - NADPH oxidase, 377, 379–381
 - Naïve T cells stimulation
 - antigenicity, adaptive immune system, 34
 - antigen-presenting cells, 32
 - bioactivation, 32–33
 - immune response, 32
 - immunogenicity, innate immune system, 33–34
 - reactive compounds generation, liver, 33
 - Na⁺/K⁺-ATPase, 82–84
 - Natural killer cells (NKT), 385, 386
 - Nephrolithiasis, 127–128
 - Neutropenia
 - clinical findings, 71, 73
 - diagnosis, 71
 - drug-induced, 70, 72
 - drugs implicated in, 71
 - pathogenesis, 70, 72
 - treatment, 72
 - Neutrophils, 381, 386, 387
 - ADRs affecting, 62, 70–72
 - Nevirapine (NVP), 179–182, 437–448
 - animal model, 181
 - bioactivation, 181, 182
 - hepatotoxicity, 180–183
 - metabolism, 180, 181
 - skin rash, 180, 181
 - Nevirapine-induced skin rash, 202–203
 - New chemical entities (NCE), 458, 459
 - NF-κB, 276, 290, 291, 293, 296, 297
 - Nitric oxide (NO), 274, 275, 285, 288–290, 378, 386
 - 3-Nitrotyrosine, 378
 - N*-methyl piperazine derivative, 535, 536
 - Nomogram, 373
 - Non-pharmacologically mediated toxicities
 - acute phase reactions, 467–468
 - immunogenicity, 468–469
 - manufacturing and product quality, 469–470
 - Nonsteroidal anti-inflammatory drugs (NSAID)
 - hemodynamically-mediated kidney injury, 115–116
 - tubulointerstitial disease, 121
 - Nrf1, 236–240
 - Nrf-2
 - Neh domains, 235
 - Nrf2^{-/-} animals, 237, 249–251
 - phosphorylation, 241–242
 - regulation of GCL, 276, 285, 289
 - role in APAP-induced liver injury, 275, 276
 - ubiquitination, 240–241
 - Nrf3, 238
 - Nuclear factor kappa B (NF-κB), 155–156
 - Nuclear receptor superfamily, 147–148
- O**
- Oral sodium phosphate solution (OSPS), 123–124
 - Organic anion transporting polypeptide (OATP) transporters, 425
 - Osmotic nephrosis, 120
 - Oxazolidinedione (OZD) derivative, 523
 - Oxidative damage, 137, 138, 152–154, 156
 - Oxidative stress, 144–145, 151–152, 375, 377–384, 386, 389, 393, 394

8-Oxoguanine, 154, 156
 Oxoguanine glycosylase 1 (OGG1), 156

P

P450, 446, 447, 503
 Papillary necrosis, 124
 Paracetamol, 370
 Pathogen-associated molecular pattern (PAMP), 495, 500, 502
 Penicillamine, 505
 Peroxisome proliferator activated receptor- γ (PPAR γ), 523
 Peroxynitrite (ONOO $^-$), 274–276, 288, 316, 378, 380, 382, 383
 Pharmacodynamic pathways, 480
 Pharmacogenetics, 412–415
 Pharmacological interaction (p-i) hypothesis, 446, 448
 Pharmacological interactions (p-i) concept
 chemokine receptor (CCR), 38, 40
 drug hypersensitivity, 41
 peptide-specific TCR, 36, 41
 sensitization, 35
 skin symptoms, 36–39
 Pharmacologically mediated toxicities
 bevacizumab, 462–465
 interleukin-12 (IL-12), 461–462
 trastuzumab, 459–460
 Phenytoin, 133–135, 148–151, 153, 155–156
 P450 inactivation mechanism, 535–536
 Pioglitazone, 421, 427
 Plasminogen activator inhibitor-1 (PAI), 288, 290
 Platelets
 ADRs affecting, 62–69, 71
 autoantibodies against, 65
 Platin-containing compounds, 118–119
 Polymorphic ventricular tachycardia, 81
 Post-translational protein redox modifications
 covalent binding, 275–277
 critical cysteines, 290
 disulfide bonds, 275
 glutathionylation, 275
 hydroxylation, 277
 nitration, 275, 276

 nitrosylation, 275
 Pregnancy, 349–350
 Proliferating cell nuclear antigen (PCNA), 391
 Prostaglandin H synthase (PHS), 132, 147, 149–152
 Protein translation-associated toxicity, 429–430
 Proteomic analyses, 374
 Proximal tubular necrosis, 371
 Pure red cell aplasia (PRCA), 470
 Purkinje fiber, 79–81, 85, 87, 88, 95

Q

QT interval, 81, 87, 89, 90, 95, 96
 QT syndrome, 81, 89, 96
 Quinone, 424
 Quinone metabolite, 419, 424
 Quinone methide, 447

R

Rat (model), 441–443, 445, 446
 Reactive intermediate-mediated mechanisms, 134–138, 143, 149–151
 antioxidants and antioxidative enzymes, 154–155
 bioactivation, 151
 cellular macromolecules, oxidative damage, 153–154
 electrophilic reactive intermediates, 134–138, 143, 149–151
 free radical, 131–132, 135, 149, 151–152
 oxidative DNA damage, 156
 oxidative stress and reactive oxygen species (ROS), 152
 reactive nitrogen species (RNS), 153
 ROS/RNS-mediated signal transduction, 156
 Reactive metabolites, 165–186, 269, 270, 272, 274, 277, 280, 294–297, 301, 372, 381, 388, 394, 423, 424, 439, 441, 446, 448, 498–500, 503, 504
 free radicals, 168, 169
 hard electrophiles, 169, 170
 soft electrophiles, 169, 170
 Reactive nitrogen species (RNS), 153, 156

Reactive oxygen species (ROS), 132, 135, 137–138, 145, 149, 151–156, 152, 269, 274–282, 284, 286, 287, 293–301, 428

Receptor-mediated mechanisms

- aryl hydrocarbon receptor (AHR), 139–147
- nuclear receptor superfamily, 147–148

Receptor of advanced glycation end products (RAGE), 500, 501

Receptors, 78, 81–83, 96, 97

- aryl hydrocarbon receptor (AHR), 132, 135, 139–148
- constitutive androstane receptor (CAR), 139, 148
- pregnane X receptor (PXR), 139, 148
- retinoic acid receptor (RAR), 135, 139, 146, 148

Rechallenge, 443–446

Recombinant IFN- α , 204

Rectifier current, 84, 89

Red blood cells

- ADRs affecting, 58–62
- autoantibodies against, 60

Renal ischemia, 118

Repair, 385, 389–392, 394

Repolarization, 78, 80, 84, 87–90, 95, 97, 98, 100, 101

Reverse use dependence, 95–97

Roadmap

- Amadori-like process, 533
- compound 12 metabolism, 531, 532
- compound 13 metabolism, 532, 533
- covalent binding and bioactivation, 530, 531
- α -keto lactam derivative, 532
- metabolic activation, drug discovery, 530, 531

Rosiglitazone, 421, 427

S

S100, 500, 501

Sarcoplasmic reticulum, 78, 80, 100

Self-nonselself, 494–495

Serum creatinine concentration, 119

Sex predisposition, 442

Signal transducer and activator of transcription (STAT 3), 387, 391

Signal transduction, 132, 135, 138, 149, 152–153, 155–156

SJS/TEN, 201

Skin rash, 438–446, 448

Statin-induced muscle toxicity, 484–485

Stem cell factor (SCF), 287, 290, 296

Sterile neutrophilic inflammations, 43

Stevens Johnson syndrome (SJS), 47, 48

Sulfamethoxazole, 502, 504

Sulfation/sulfate conjugate, 447

Superagonist anti-CD28 monoclonal antibody, 465–467

Superoxide, 377–380, 382, 383, 391

Superoxide anion radical ($O_2^{\bullet-}$), 315

Superoxide dismutase (SOD), 152

T

Tamoxifen, 178, 179

- bioactivation, 178, 179

T cell-mediated drug hypersensitivity effector cells, 43

- Gell and Coombs classification, 41, 42
- hapten model, 35, 37, 39
- p-i concept, 36–39
- sterile neutrophilic inflammations, 43
- Th1-type immune reactions, 41–43
- Th2-type immune response, 43

T cells, 439, 443–446

Teratogenesis, 131–138, 142–148, 150–151, 156

- aryl hydrocarbon receptor (AHR), 139–147
- birth defects, 131, 133–134, 137
- competing mechanisms, 137, 138
- conversion/bioactivation, 135
- electrophilic reactive intermediates, 149–150
- embryonic and fetal development, 133–134
- enzymatic pathways, 137
- free radical reactive intermediates, 151–156
- functional birth defects, 131, 133–134, 150
- mother vs. embryo and fetus, drug metabolism, 137–138
- nuclear receptor superfamily, 147–148

- receptor vs. reactive intermediate-mediated mechanisms, 134, 136
 - 2,3,7,8-Tetrachlorodibenzo-p-dioxin (“dioxin”) (TCDD), 133, 140–142, 145–147
 - Thalidomide, 133–135, 151, 156
 - Thiazolidinedione (TZD) ring-system, 523
 - Thiazolidinediones, 419–421
 - Thrombin inhibitor, 408
 - Thrombocytopenia
 - autoantibody-induced, 65
 - clinical findings, 67, 68, 71, 73
 - diagnosis, 68, 69
 - drug-induced, 62, 65, 67, 69, 71
 - drugs causing, 67
 - heparin-induced, 66
 - naproxen-induced, 69
 - pathogenesis, 62–67
 - treatment, 69
 - Thymidine triphosphate (TTP) depletion, 334
 - Tienilic acid, 503, 504
 - TNF- α , 211–212, 384–388, 390, 391, 394
 - TNF- α blockers, 204
 - Tolerance, 439, 443, 445, 446
 - Toll-like receptors, 500–502, 505, 506
 - Torsade de pointes, 87, 89–91, 95–98, 100
 - Toxic epidermal necrolysis (TEN), 47–49
 - Trastuzumab, 459–460
 - Triangulation, 95–98
 - Troglitazone, 269, 271, 293–295, 297, 299
 - Troglitazone-induced hepatotoxicity
 - biomarkers, 424–425
 - cytotoxicity, 423–424
 - hepatic drug transporters, inhibition, 425–426
 - hypersensitivity reaction, 426–427
 - kinase-mediated cell toxicity pathway, 428–429
 - mechanisms, 427–430
 - metabolism, 420–421
 - mitochondria-mediated toxicity, 428
 - protein translation-associated toxicity, 429–430
 - reactive metabolites, 422–424
 - stable metabolites, metabolism, 421–422
 - Tryptophan, 497
 - Tubular epithelial cell damage
 - acute tubular necrosis, 117–120
 - osmotic nephrosis, 120
 - Tubulointerstitial disease
 - acute allergic interstitial nephritis (AIN), 120–121
 - chronic interstitial nephritis, 121–123
 - nephrocalcinosis, 123–124
 - papillary necrosis, 124
 - Tumor necrosis factor (TNF), 283, 290–293, 296–298, 302
 - Tunel assay, 389
 - Two phase mechanism, 375
- U**
- UDP-glucuronosyltransferase (UGT), 137–138, 144
 - UGT1A1, 144, 422
 - UGT1A6, 144
 - UGT1A8, 422
 - UGT1A10, 422
- V**
- Vaccines, 496
 - non-pharmacological effects, 471–472
 - pharmacological effects, 471
 - Vascular endothelial growth factor (VEGF), 288, 391, 392, 394, 462–465
 - Vasoconstriction, 116
 - Ventricular fibrillation, 80, 81, 90
 - Ventricular tachycardia, 80, 81, 87, 100
 - Viral infections, 348–349
- W**
- Western blot, 373
- X**
- Xenobiotics
 - AHR, 145
 - bioactivation, 151
 - biochemical pathways, 152
 - embryonic and fetal development, 133, 134
 - Ximelagatran, 407–417
- Z**
- Zidovudine (AZT), 333